BocaGreenMD, Inc. Launches Line of Generic Prescription Prenatal Multivitamins
BocaGreenMD, Inc. announced that on November 6, 2012 it will launch the Prena1™ line of generic prescription prenatal vitamins.
Boca Raton, FL (PRWEB) November 01, 2012
BocaGreenMD, Inc. ("BocaGreenMD”), announced that on November 6, 2012 it will launch the Prena1™ line of generic prescription prenatal vitamins.
Prena1 Plus is a comprehensive single dose dietary supplement containing one prenatal tablet with 16 vitamins and minerals, plus one softgel with 300 mg of plant-based DHA.
Prena1 is a convenient, single daily softgel with 14 vitamins, minerals, and 200 mg of plant-based DHA.
Prena1 Chew is a single daily easy to chew, vanilla flavored, chewable tablet ideal for women planning a pregnancy and those with difficulty swallowing tablets or capsules, or where nausea or morning sickness makes taking tablets or capsules difficult.
All Prena1 multivitamins contain a unique combination of folic acid and plant-based DHA.
Jason Spitz, Chief Marketing Officer of BocaGreenMD, stated, "We are very excited to introduce our Prena1 prenatal multivitamins with a unique combination of folic acid and plant-based DHA. Prena1 prenatal multivitamins will be welcomed by health care providers and pharmacists as innovative generic products that offer patients and customers a cost-effective choice without sacrificing quality. Prena1, Prena1 Plus, and Prena1 Chew are available by prescription only at chain, independent, and mail order pharmacies throughout the United States.”
BocaGreenMD is a pharmaceutical company that focuses on developing authorized generics for women's health products. Creating value and savings for the consumer without sacrificing quality will drive innovation at BocaGreenMD. Questions may be directed to Daniel A. Cartwright, BocaGreenMD's Chief Financial Officer, at (561) 961-1911. More information on BocaGreenMD and its products are available at http://www.bocagreenmd.com or http://www.prena1.com.
For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2012/11/prweb10080743.htmView Comments and Join the Discussion!